THR-149

New data announced for
Phase 2 Part A study in DME

Read the full press release

 

Business Update

2021 Full Year Results
and 2022 Outlook

To the press release

 

Tom Graney, CFA appointed CEO of Oxurion

Read the full press release

 

Capital Commitment

Oxurion NV enters into a Capital Commitment of up to €30 Million with Negma Group

Read More

 

Review article

Potential of Pan-RGD integrin antagonists for treatment of retinal vascular disorders

Read more

 

Our mission

To prevent vision loss and address unmet medical needs in retinal disorders

Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

Investors

Back of the eye disorders

At Oxurion we are dedicated to developing innovative treatments to preserve vision for patients with diseases affecting the back of the eye. The company has built a diverse portfolio of disease-modifying therapies, including treatments for diabetic eye disease, a leading cause of blindness in people of working age worldwide.

Read more

Focus on patients

Pipeline

Intensive preclinical research, as well as our deep scientific knowledge of diseases affecting the back of the eye, has led to the development of disease-modifying therapies aimed to preserve patients’ vision. Our current pipeline of candidates is focused on new treatment approaches to diabetic eye disease and macular disorders.

Read more

Jetrea®

Investors

Oxurion is listed on Euronext Brussels under the symbol OXUR. Check our Investors pages to find more information about extraordinary and annual shareholders meetings and learn more about the full year results, half year results and business reviews by Oxurion, or download our publications and reports.

Read more

Advancing Science. Enhancing Vision.

Oxurion builds on years of experience resulting from local and international scientific collaboration. With our pipeline of innovative drug candidates for retinal disorders, we have a clear mission: to deliver solutions enabling vision preservation for people around the globe.  

We are advancing our pipeline of drug candidates to preserve vision for patients with retinal disorders and look forward to sharing the progress of our clinical programs.

- Patrik De Haes, MD, Non-Executive Chairman of Oxurion

 

Stock Quote

Careers

Oxurion employees are united by a shared goal: to make Oxurion a global leader in developing innovative treatments for retinal disorders including diabetic macular edema (DME). Want to join us?

Visit our careers site

Partnerships

Oxurion relies on a network of experienced partners to bring the best possible eye care to patients across the globe. We are always open to new opportunities for partnership and collaboration for improving eye care.

Want to become a partner? Contact us!

Stay in touch

Be sure to check in regularly for the latest news about our our company, research & development activities and updates for investors or just subscribe to our mailing list to receive regular updates.

Read our latest news or Subscribe